BR112016011091B1 - Sequência de endolisina kz144 modificada - Google Patents
Sequência de endolisina kz144 modificada Download PDFInfo
- Publication number
- BR112016011091B1 BR112016011091B1 BR112016011091-9A BR112016011091A BR112016011091B1 BR 112016011091 B1 BR112016011091 B1 BR 112016011091B1 BR 112016011091 A BR112016011091 A BR 112016011091A BR 112016011091 B1 BR112016011091 B1 BR 112016011091B1
- Authority
- BR
- Brazil
- Prior art keywords
- seq
- amino acid
- sequence
- polypeptide
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2013/073869 WO2015070911A1 (en) | 2013-11-14 | 2013-11-14 | Modified kz144 endolysin sequence |
| EPPCT/EP2013/073869 | 2013-11-14 | ||
| PCT/EP2014/074671 WO2015071436A1 (en) | 2013-11-14 | 2014-11-14 | Modified kz144 endolysin sequence |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016011091A2 BR112016011091A2 (pt) | 2017-12-05 |
| BR112016011091B1 true BR112016011091B1 (pt) | 2024-02-06 |
Family
ID=49582760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016011091-9A BR112016011091B1 (pt) | 2013-11-14 | 2014-11-14 | Sequência de endolisina kz144 modificada |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10184120B2 (https=) |
| JP (1) | JP6745720B2 (https=) |
| KR (1) | KR102302044B1 (https=) |
| CN (1) | CN105793419B (https=) |
| AU (1) | AU2014350104B2 (https=) |
| BR (1) | BR112016011091B1 (https=) |
| CA (1) | CA2929686C (https=) |
| EA (1) | EA035959B1 (https=) |
| MX (1) | MX374403B (https=) |
| WO (2) | WO2015070911A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4115897A1 (en) | 2015-09-17 | 2023-01-11 | Contrafect Corporation | Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby |
| CA3022334A1 (en) * | 2016-04-28 | 2017-11-02 | Lysando Ag | Antimicrobial agents against salmonella bacteria |
| WO2017203471A1 (en) * | 2016-05-27 | 2017-11-30 | Sasinapas Co., Ltd. | Endolysin variant |
| WO2018100408A1 (en) * | 2016-11-30 | 2018-06-07 | Sasinapas Co.,Ltd. | Modified peptides |
| MX2019011808A (es) * | 2017-04-03 | 2020-01-09 | Sasinapas Co Ltd | Endolisinas de gram-negativas modificadas. |
| WO2019229184A1 (en) * | 2018-05-30 | 2019-12-05 | Lysando Ag | Novel antimicrobial fusion proteins |
| CN111304181B (zh) * | 2020-02-17 | 2021-11-23 | 华东理工大学 | 一种基因工程改造后的副溶血性弧菌噬菌体裂解酶及其制备方法和应用 |
| KR20250044545A (ko) | 2023-09-23 | 2025-04-01 | 조배근 | 사료급이기 청소기 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1289092C (en) * | 1987-01-15 | 1991-09-17 | Novartis Vaccines And Diagnostics, Inc. | Thermostable human cu/zn superoxide dismutase muteins |
| EP0285123A3 (en) * | 1987-04-03 | 1989-02-01 | Stabra AG | A method for complete mutagenesis of nucleic acids |
| ZA936811B (en) * | 1992-10-28 | 1995-03-15 | Upjohn Co | Somatotropin modifications |
| JPH08127540A (ja) * | 1994-09-09 | 1996-05-21 | Takeda Chem Ind Ltd | 抗潰瘍医薬 |
| WO2009024327A2 (en) * | 2007-08-22 | 2009-02-26 | Profos Ag | New proteins for use in human and animal staphylococcus infections |
| GB0815484D0 (en) | 2008-08-26 | 2008-10-01 | Univ Leuven Kath | Antibacterial agents |
| PL2445515T3 (pl) * | 2009-06-26 | 2016-10-31 | Środki przeciwdrobnoustrojowe | |
| AU2010264659B2 (en) | 2009-06-26 | 2016-08-04 | Lysando Aktiengesellschaft | Antimicrobial agents |
| KR20120059576A (ko) * | 2009-08-24 | 2012-06-08 | 뤼산도 홀딩 아게 | 신규한 엔도리신 ＯＢＰｇｐＬＹＳ |
| SG184836A1 (en) * | 2010-04-27 | 2012-11-29 | Lysando Ag | Method of reducing biofilms |
| GB201018518D0 (en) * | 2010-11-03 | 2010-12-15 | Univ Leuven Kath | Novel endolysin |
| EP2468856A1 (en) | 2010-12-23 | 2012-06-27 | Lysando Aktiengesellschaft | Antimicrobial Agents |
| KR20130142837A (ko) * | 2012-06-20 | 2013-12-30 | 한국외국어대학교 연구산학협력단 | 슈도모나스 에루기노사의 박테리오파아지 및 그 용도 |
-
2013
- 2013-11-14 WO PCT/EP2013/073869 patent/WO2015070911A1/en not_active Ceased
-
2014
- 2014-11-14 EA EA201691004A patent/EA035959B1/ru not_active IP Right Cessation
- 2014-11-14 WO PCT/EP2014/074671 patent/WO2015071436A1/en not_active Ceased
- 2014-11-14 MX MX2016006277A patent/MX374403B/es active IP Right Grant
- 2014-11-14 BR BR112016011091-9A patent/BR112016011091B1/pt not_active IP Right Cessation
- 2014-11-14 AU AU2014350104A patent/AU2014350104B2/en active Active
- 2014-11-14 JP JP2016531660A patent/JP6745720B2/ja active Active
- 2014-11-14 CA CA2929686A patent/CA2929686C/en active Active
- 2014-11-14 US US15/036,569 patent/US10184120B2/en active Active
- 2014-11-14 CN CN201480062330.1A patent/CN105793419B/zh active Active
- 2014-11-14 KR KR1020167015821A patent/KR102302044B1/ko active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160085342A (ko) | 2016-07-15 |
| WO2015071436A1 (en) | 2015-05-21 |
| JP2016537979A (ja) | 2016-12-08 |
| KR102302044B1 (ko) | 2021-09-15 |
| US20160281074A1 (en) | 2016-09-29 |
| CN105793419A (zh) | 2016-07-20 |
| EA201691004A1 (ru) | 2017-01-30 |
| US10184120B2 (en) | 2019-01-22 |
| MX374403B (es) | 2025-03-06 |
| BR112016011091A2 (pt) | 2017-12-05 |
| CA2929686A1 (en) | 2015-05-21 |
| AU2014350104B2 (en) | 2020-03-05 |
| CN105793419B (zh) | 2021-06-01 |
| WO2015070911A1 (en) | 2015-05-21 |
| CA2929686C (en) | 2023-08-08 |
| EA035959B1 (ru) | 2020-09-07 |
| MX2016006277A (es) | 2017-01-05 |
| JP6745720B2 (ja) | 2020-08-26 |
| AU2014350104A1 (en) | 2016-05-12 |
| NZ719338A (en) | 2022-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016011091B1 (pt) | Sequência de endolisina kz144 modificada | |
| Sun et al. | Small heat shock proteins: molecular structure and chaperone function | |
| Yoon et al. | Xenopus Staufen is a component of a ribonucleoprotein complex containing Vg1 RNA and kinesin | |
| Helfer et al. | Endosomal recruitment of the WASH complex: active sequences and mutations impairing interaction with the retromer | |
| US10167462B2 (en) | Modified EL188 endolysin sequence | |
| Parthasarathy et al. | Expression and purification of coronavirus envelope proteins using a modified β-barrel construct | |
| Güngör et al. | The ER membrane complex (EMC) can functionally replace the Oxa1 insertase in mitochondria | |
| WO2017094885A1 (ja) | リガンド蛍光センサータンパク質とその使用 | |
| Jaradat et al. | Solid-phase synthesis and antibacterial activity of an artificial cyclic peptide containing two disulfide bridges | |
| Aoki et al. | Sec22b-dependent assembly of endoplasmic reticulum Q-SNARE proteins | |
| Fernandes et al. | Mapping the interactions between a RUN domain from DENND5/Rab6IP1 and sorting nexin 1 | |
| Azmi et al. | Introduction of cell‐selectivity in bovine cathelicidin BMAP‐28 by exchanging heptadic isoleucine with the adjacent proline at a non‐heptadic position | |
| Galesic et al. | Investigating the effects of O-GlcNAc modifications in Parkinson’s disease using semisynthetic α-synuclein | |
| EP3068877B1 (en) | Modified kz144 endolysin sequence | |
| Sladewski et al. | Molecular features of Myosin F adapted for driving actin flows in Toxoplasma gondii | |
| NZ719338B2 (en) | Modified kz144 endolysin sequence | |
| HK1228944B (en) | Modified kz144 endolysin sequence | |
| HK1228944A1 (en) | Modified kz144 endolysin sequence | |
| EP3068878B1 (en) | Modified el188 endolysin sequence | |
| Pearce | Exploring the Heart of MyBP-C. | |
| Markovic | Protein quality control systems in muscle: From disease to mechanism | |
| Wang | Transmembrane helix-helix interactions in a bacterial small multidrug transport protein | |
| Jefri | Characterization of the mutations associated with Cystic Fibrosis in the C-terminal region of the Cystic Fibrosis transmembrane conductance regulator (CFTR) | |
| Drake III | Regulating the stabilities of NOD1 and NOD2, two innate immune receptors, with sugars and chaperones | |
| Srinivasan | Molecular basis of the differences in fibrillogenicity between SAA1. 1 and SAA2. 2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/11/2014, OBSERVADAS AS CONDICOES LEGAIS |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2854 DE 16-09-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |